NetworkNewsBreaks – AnPac Bio-Medical Science Co
Post# of 61
(Total Views: 264)
Posted On: 11/15/2021 2:51:16 PM
NetworkNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Uniquely Positioned in Cancer Screening, Detection Market
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is the company behind a proprietary novel technology for early cancer screening and detection — the Cancer Differentiation Analysis (“CDA”). Powered by a database containing over 200,000 samples and cases, AnPac Bio’s CDA technology can detect and carry multifaceted information, including cellular and protein-level details, to determine the existence of cancerous environments. At present, the company’s CDA platform “can detect up to 26 different types of cancer, which gives AnPac Bio a major advantage over industry peers in terms of cost effectiveness, multi-cancer testing, ability to detect cancer early with high sensitivity and specificity,” reads a recent article. “With its proprietary technology and being one of the first companies in the world to introduce the concept of multi-level, multi-parameter and multi-cancer (pan-cancer) screening approaches, AnPac Bio is uniquely positioned to be a leader among other prominent cancer screening and detection blood testing companies.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is the company behind a proprietary novel technology for early cancer screening and detection — the Cancer Differentiation Analysis (“CDA”). Powered by a database containing over 200,000 samples and cases, AnPac Bio’s CDA technology can detect and carry multifaceted information, including cellular and protein-level details, to determine the existence of cancerous environments. At present, the company’s CDA platform “can detect up to 26 different types of cancer, which gives AnPac Bio a major advantage over industry peers in terms of cost effectiveness, multi-cancer testing, ability to detect cancer early with high sensitivity and specificity,” reads a recent article. “With its proprietary technology and being one of the first companies in the world to introduce the concept of multi-level, multi-parameter and multi-cancer (pan-cancer) screening approaches, AnPac Bio is uniquely positioned to be a leader among other prominent cancer screening and detection blood testing companies.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)